Protalix BioTherapeutics, Inc. (PLX) Stock

Protalix BioTherapeutics, Inc. (PLX) is a Healthcare stock trading at $2.21 (as of 2026-06-18), with a market capitalization of $170.01M and a trailing P/E of 11.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins using its ProCellEx plant cell-based expression system, with operations in the United States and other international markets. It offers Elelyso for Gaucher disease and has product candidates including PRX-102, PRX-110, PRX-115, and PRX-119.

Valuation — source: SEC EDGAR (first-party)
Price	$2.21
Market Cap	$170.01M
P/E Ratio	11.1
EV / EBITDA	6.1
Price / Book	2.53
Price / Sales	2.23
DCF Value (model)	$-2.70
DCF Upside vs Price	-222.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$52.74M
Net Margin	-12.5%
Return on Equity	22.8%
Current Ratio	3.15
Revenue Growth (YoY)	233.7%
EPS Growth (YoY)	-560.0%
FCF Growth (YoY)	-496.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.41 (distress)

Valuation vs Sector & Industry
Stock P/E	11.1
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-46.8%
vs Industry	-34.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($7.85M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Dror Bashan
Employees	213
Country	US
IPO Date	1998-05-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.